Navigation Links
Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
Date:4/23/2013

SEATTLE, April 24, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter financial results on Thursday, May 2, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update, at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:

Thursday, May 2
1:30 p.m. PT/4:30 p.m. ET/10:30 p.m. CET
1-877-941-6010 (domestic)
+1 480-629-9644 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI's website, www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-358-3474 (domestic) or +1 303-590-3030 (international). The access code for the replay is #4615670. The telephone replay will be available until Thursday, May 9, 2013.

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com.

Media and Investor Contacts:

Cell Therapeutics, Inc.

Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.272.4345
invest@ctiseattle.com

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
Elena Bellacicca

E: CTI_EUInvestors@CTI-Lifesciences.com
T: +39 02 89659700
F: +39 02 89659719
http://www.celltherapeutics.com/italiano

 


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
2. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
3. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
4. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
5. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
6. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
7. Aratana Therapeutics Adds To Drug Development Team
8. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
9. Novira Therapeutics Completes $25 Million Series A Financing
10. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
11. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016 /PRNewswire/ - Resverlogix Corp. ... the independent Data and Safety Monitoring Board (DSMB) ... high-risk cardiovascular disease (CVD) patients has completed a ... study should continue as planned without any modifications. ... that no safety or efficacy concerns were identified. ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension for ... funded research and development is welcome news for the photonics community, say leaders ... As part of the National Defense Authorization Act (NDAA) compromise agreement finalized today ...
(Date:12/2/2016)... , Dec. 2, 2016 More than $4.3 million ... Helix Medals dinner ( DHMD ). The gala was held at ... New York City and honored Alan Alda ... respectively, to health and medicine and the public understanding of ... in 2006, the event has raised $40 million for the ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ACEA Biosciences, ... its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer ... providing an update on the phase I/II clinical trials for AC0010 in patients with ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):